Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Karyopharm Therapeutics Inc. - Common Stock
(NQ:
KPTI
)
0.0174
-0.0226 (-56.50%)
Delayed Quote
Updated: 4:00 PM EST, Nov 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Karyopharm Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
After-Hours Stock Movers: KPTI Rises 140%, STAK Falls 51.5% After US Close
↗
November 10, 2026
Via
Chartmill
Today's US Session Top Gainers and Decliners: PEPG, OPENZ and TTEC Rise; IHRT, BMGL and MVST Fall
↗
November 10, 2026
Via
Chartmill
Top US Market Movers: Today's Session Gainers and Losers
↗
November 10, 2026
Via
Chartmill
US Gap-Up and Gap-Down Stocks: Nov. 10, 2026 Session
↗
November 10, 2026
Via
Chartmill
Most Active US Stocks: Nov. 6, 2026
↗
November 06, 2026
Via
Chartmill
Karyopharm Therapeutics Inc (NASDAQ:KPTI) Posts Q1 Beat and Highlights ASCO Presentation, Shares Surge 7%
↗
May 14, 2026
Via
Chartmill
Premarket Movers Nov. 10, 2026: Gainers and Losers
↗
November 10, 2026
Via
Chartmill
Nov. 9 After-Hours Movers: Gainers and Losers
↗
November 09, 2026
Via
Chartmill
US Session Top Movers: FISN, XHLD, TLS Lead Gainers; ZURA, SOC, PLCE Lead Losers
↗
November 09, 2026
Via
Chartmill
Top Movers Today: MF Gains 89.56%, ZURA Falls 72.98%
↗
November 09, 2026
Via
Chartmill
After-Hours Market Movers: Gainers and Decliners From Today's U.S. Session
↗
November 06, 2026
Via
Chartmill
Premarket Movers: Gainers and Decliners on Nov. 5, 2026
↗
November 05, 2026
Via
Chartmill
Premarket Movers Nov. 2, 2026: Gainers and Losers
↗
November 02, 2026
Via
Chartmill
Top US Stock Movers in Today's Session
↗
October 28, 2026
Via
Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session.
↗
September 11, 2026
Via
Chartmill
Traders are paying attention to the gapping stocks in Friday's session.
↗
September 11, 2026
Via
Chartmill
Which stocks are moving before the opening bell on Friday?
↗
September 11, 2026
Via
Chartmill
Karyopharm (KPTI) Q2 2026 Earnings Call Transcript
↗
August 20, 2026
Biotech pivots to hematology after endometrial cancer setback, faces debt deadline.
Via
The Motley Fool
Topics
Earnings
Karyopharm Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript
↗
August 13, 2026
Karyopharm Therapeutics (NASDAQ:KPTI) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is...
Via
Benzinga
Topics
Earnings
Top movers in Friday's session
↗
July 31, 2026
Via
Chartmill
Top stock movements in today's session.
↗
July 31, 2026
Via
Chartmill
Gapping stocks in Friday's session
↗
July 31, 2026
Via
Chartmill
Friday's pre-market session: top gainers and losers
↗
July 31, 2026
Via
Chartmill
Thursday's after hours session: top gainers and losers
↗
July 30, 2026
Via
Chartmill
Which stocks are moving on Monday?
↗
July 20, 2026
Via
Chartmill
Karyopharm Therapeutics Spotlights Selinexor Milestones, ASCO Data and Cancer Trial Readouts
↗
May 26, 2026
Karyopharm Therapeutics (NASDAQ:KPTI) executives used an H.C. Wainwright BioConnect Conference appearance to highlight upcoming clinical and regulatory milestones for selinexor, the company’s oral...
Via
MarketBeat
Karyopharm Therapeutics Teases ASCO SENTRY Data as FDA Path Comes Into Focus
↗
May 26, 2026
Karyopharm Therapeutics (NASDAQ:KPTI) executives said the company expects to provide a fuller presentation of its Phase 3 SENTRY trial data for selinexor in myelofibrosis at the upcoming ASCO...
Via
MarketBeat
Karyopharm (KPTI) Q1 2026 Earnings Transcript
↗
May 14, 2026
Karyopharm (KPTI) Q1 2026 Earnings Transcript
Via
The Motley Fool
Karyopharm Therapeutics Q1 Earnings Call Highlights
↗
May 14, 2026
Karyopharm Therapeutics (NASDAQ:KPTI) said it entered 2026 with several near-term clinical and regulatory catalysts, led by new Phase 3 data in myelofibrosis and an expected midyear readout in...
Via
MarketBeat
Topics
Earnings
Karyopharm (KPTI) Q2 2025 Earnings Transcript
↗
May 04, 2026
Karyopharm (KPTI) Q2 2025 Earnings Transcript
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.